Tofacitinib 540737-29-9
Tofacitinib CAS# 540737-29-9 is described as a new, investigational oral JAK inhibitor, for the treatment of adult patients with moderate to severely active Rheumatoid Arthritis. It was developed to target the JKA protein, which is the protein that leads to joint destruction in RA patients. Both five and ten milligram doses are slated to be offered, introducing an alternative treatment to current RA drugs, such as Abbott’s injectable drug Humira.
The JAK inhibitor Tofacitinib shows preclinical promise as a therapy for ATL and HAM/TSP.
This study offers insight into new therapeutic options for adult T cell leukemia (ATL) and the neurological disorder, HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Publications
Ju et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood, 117(6):1938-1946. 2011.
| Systematic (IUPAC) name: | 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile |
|---|---|
| Tofacitinib CAS number: | 540737-29-9 |
| ATC code: | |
| PubChem: | 9926791 |
| DrugBank: | |
| Formula: | C16H20N6O1 |
| Molecular mass: | 312.369 g/mol |
| Tofacitinib Assay/Purity: | Typically NLT 98% |
